Therapeutics

Top Story

FDA withdraws biosimilar draft guidance following public comments

FDA withdraws biosimilar draft guidance following public comments
June 21, 2018
FDA News

FDA approves Rituxan for pemphigus vulgaris

June 8, 2018
The FDA has approved rituximab for the treatment of adult patients with moderate-to-severe pemphigus vulgaris, a rare autoimmune blistering disease that affects the skin…
In the Journals

Adalimumab associated with improvements in nail psoriasis

October 31, 2017
Twenty-six weeks of treatment with adalimumab was associated with improvements in a number of fingernail psoriasis outcomes compared with placebo, according to recent…

IL-12 therapy elicits encouraging response rates in melanoma

October 25, 2017
Immunopulse IL-12 monotherapy and in combination with pembrolizumab was associated with encouraging response rates and safety data in patients with melanoma who may not…
More Headlines »
Healio Jobs